CSI Market
Sign In | Register

Bellicum Pharmaceuticals Inc (BLCM) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access BLCM Annual Cash Flow →
Cash flow data covering Bellicum Pharmaceuticals Inc–Sep 30 2022 offers a view into how Sep 30 2023's cash position has developed alongside business activity.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2023)
9 Months 		(Jun 30 2023) (Mar 31 2023) (Dec 31 2022) (Sep 30 2022)
Operating Activities
Income-16.18
Depreciation & amortization0.01
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Impairment of Intangible Assets, Finite-lived0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total0.00
Share-based Compensation0.73
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants-0.29
Operating Lease Right Of Use Asset Amortization0.03
Gain Loss On Disposition Of Assets Normal Course Of Business-
Operating Lease Right Of Use Asset Amortization Expense-
Amortization of Lease Liability-
Tangible Asset Impairment Charges-
Income taxes0.00
Gain (Loss) on Investments0.00
Increase (Decrease) in Other Receivables-0.02
Increase (Decrease) in Accounts Payable0.04
Increase (Decrease) in Accrued Liabilities-1.27
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets1.04
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-15.94
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.02
Proceeds from Sale and Maturity of Marketable Securities0.00
Payments to Acquire Marketable Securities0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Proceeds from Sale, Maturity and Collection of Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.01
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Paymentofissuancecostsonpreferredstock-
Proceedsfromexerciseofpreferredwarrants-
Finance Lease Principal Payments-0.04
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.00
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-15.93
Total Cash Flow-15.93
4 historic quarters locked

Sign in to unlock the full Bellicum Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Bellicum Pharmaceuticals Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001628280-23-038953

Figures are derived from filed reports and may be restated. Historical data is subject to revision.